Drug Profile
Research programme: OX40 based therapeutics - Genentech
Alternative Names: Anti-OX40L; CD134; CTB OX40; CTB-134LLatest Information Update: 24 Oct 2021
Price :
$50
*
At a glance
- Originator Xenova Group
- Class Differentiation antigens; Membrane glycoproteins; Recombinant fusion proteins; Tumour necrosis factors
- Mechanism of Action T cell activation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Autoimmune disorders; Cancer; Inflammation; Inflammatory bowel diseases; Rheumatoid arthritis
Most Recent Events
- 26 Apr 2002 Genentech has signed a worldwide licensing agreement with Xenova
- 22 Nov 2001 Preclinical development for Rheumatoid arthritis in United Kingdom (Unknown route)
- 28 Jun 2001 Cantab Pharmaceuticals has been acquired by Xenova Group